ESEkim Seven

Ekim Seven

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ekim Seven has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Allan Linneberg

    Center for Clinical Research and Prevention, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark

    4 shared publications
  • Hans Ibsen

    Department of Internal Medicine, Holbæk Hospital, University of Copenhagen, Holbæk, Denmark

    4 shared publications
  • Jørgen L. Jeppesen

    Department of Internal Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark

    3 shared publications
  • Kristian Wachtell

    Department of Internal Medicine, Glostrup Hospital, University of Copenhagen, Glostrup, Denmark

    3 shared publications
  • Lise L. N. Husemoen

    Research Centre for Prevention and Health, The Capital Region of Denmark, Glostrup, Denmark

    2 shared publications
  • Anders Barasa

    Department of Cardiology, Amager-Hvidovre University Hospital, Copenhagen, Denmark (M.P., A.B.).

    1 shared publication

Latest Publications

  • Open Access

    Artificial Intelligence-Assisted Lung Perfusion Quantification from Spectral CT Iodine Map in Pulmonary Embolism

    by Reza Piri, Parisa Seyedhosseini, Samir Jawad, Emilie Sonne-Holm, Camilla Stedstrup Mosgaard, Ekim Seven, Kristian Eskesen, Ole Peter Kristiansen, Søren Fanø, Mathias Greve Lindholm, et al.

    Introduction: This study evaluated the performance of automated dual-energy computed tomography (DECT)-based quantification of perfusion defects (PDs) in acute pulmonary embolism and examined its correlation with clinical parameters. Methods: We retrospectively analyzed data from 171 patients treated for moderate-to-severe acute pulmonary embolism, who underwent DECT imaging at two separate time points. PDs were quantified using a fully automated AI-based segmentation method that relied exclusively on iodine perfusion maps. This was compared with a semi-automatic clinician-guided segmentation, where radiologists manually adjusted thresholds to eliminate artifacts. Clinical variables including the Miller obstruction score, right-to-left ventricular diameter ratio, oxygen saturation, and patient-reported symptoms were also collected. Results: The semiautomatic method demonstrated stronger correlations with embolic burden (Miller score; r = 0.4, p < 0.001 at follow-up) and a negative correlation with oxygen saturation (r = −0.2, p = 0.04). In contrast, the fully automated AI-based quantification consistently produced lower PD values and demonstrated weaker associations with clinical parameters. Conclusions: Semiautomatic quantification of PDs currently provides superior accuracy and clinical relevance for evaluating lung PDs in acute pulmonary embolism. Future multimodal AI models that incorporate both anatomical and clinical data may further enhance diagnostic precision.

  • Open Access

    A Randomized Controlled Trial of Thoracentesis in Acute Heart Failure

    by Signe Glargaard, Jakob Hartvig Thomsen, Christian Tuxen, Matias Greve Lindholm, Christian Axel Bang, Morten Schou, Kasper Iversen, Rasmus Vedby Rasmussen, Brian Bridal Løgstrup, Søren Vraa, et al.

    BACKGROUND: TAP-IT (Thoracentesis to Alleviate Cardiac Pleural Effusion–Interventional Trial) investigated the effect of therapeutic thoracentesis in addition to standard medical therapy in patients with acute heart failure and sizeable pleural effusion. METHODS: This multicenter, unblinded, randomized controlled trial, conducted between August 31, 2021, and March 22, 2024, included patients with acute heart failure, left ventricular ejection fraction ≤45%, and non-negligible pleural effusion. Patients with very large effusions (more than two-thirds of the hemithorax) were excluded. Participants were randomly assigned 1:1 to upfront ultrasound-guided pleural pigtail catheter thoracentesis in addition to standard medical therapy or standard medical therapy alone. The primary outcome was days alive out of the hospital over the following 90 days; key secondary outcomes included length of admission and 90-day all-cause mortality. All outcomes were analyzed according to the intention-to-treat principle. RESULTS: A total of 135 patients (median age, 81 years [25th; 75th percentile, 75; 83]; 33% female; median left ventricular ejection fraction, 25% [25th; 75th percentile, 20%; 35%]) were randomized to either thoracentesis (n=68) or standard medical therapy (n=67). The thoracentesis group had a median of 84 days (77; 86) alive out of the hospital over the following 90 days compared with 82 days (73; 86) in the control group ( P =0.42). The mortality rate was 13% in both groups, with no difference in survival probability ( P =0.90). There were no differences in the duration of the index admission (control group median, 5 days [3; 8]; thoracentesis group median, 5 days [3; 7], P =0.69). Major complications occurred in 1% of thoracenteses performed during the study period. CONCLUSIONS: For patients with acute heart failure and pleural effusion, a strategy of upfront routine thoracentesis in addition to standard medical therapy did not increase days alive out of the hospital for 90 days, all-cause mortality, or duration of index admission. The current findings lay the groundwork for future research to confirm the results. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT05017753.


  • Open Access

    Automated oxygen administration versus manual control in acute cardiovascular care: a randomised controlled trial

    by Ida Arentz Taraldsen, Johannes Grand, Jasmin Dam Lukoschewitz, Ekim Seven, Ulrik Dixen, Morten Petersen, Laura Rytoft, Marie Munk Jakobsen, Ejvind Frausing Hansen, Jens Dahlgaard Hove

    Background: Oxygen therapy is commonly administered to patients with acute cardiovascular conditions during hospitalisation. Both hypoxaemia and hyperoxia can cause harm, making it essential to maintain oxygen saturation (SpO2) within a target range. Traditionally, oxygen administration is manually controlled by nursing staff, guided by intermittent pulse oximetry readings. This study aimed to compare standard manual oxygen administration with automated oxygen administration (AOA) using the O2matic device.Methods: In this randomised controlled trial, 60 patients admitted to a cardiac department with an acute cardiovascular condition requiring oxygen therapy were randomised to either standard care (manual oxygen administration) or AOA via the O2matic device. The primary outcome was the percentage of time spent within the desired SpO2range (92%–96% or 94%–98%) over 24 hours.Results: Patients had a mean age of 75.8±12.4 years, with an average SpO2of 93%. Those in the AOA group (n=25) spent significantly more time within the target SpO2range (median 87.0% vs 60.6%, p2range was significantly lower in the AOA group (7.9% vs 33.6%, p2range were observed between the two groups.Conclusions: AOA with the O2matic device is superior to standard manual control in maintaining SpO2within the target range in patients hospitalised with acute cardiovascular conditions. The automated systems significantly reduce the time spent in hypoxaemia without increasing hyperoxia.Trial registration number: NCT05452863.


  • Open Access

    Adipocytokines, C-Reactive Protein, and Cardiovascular Disease: A Population-Based Prospective Study

    by Ekim Seven, Lise L. N. Husemoen, Thomas S. G. Sehested, Hans Ibsen, Kristian Wachtell, Allan Linneberg, Jørgen L. Jeppesen

    Being overweight or obese is associated with a greater risk of coronary heart disease and stroke compared with normal weight. The role of the specific adipose tissue-derived substances, called adipocytokines, in overweight- and obesity-related cardiovascular disease (CVD) is still unclear. To investigate the associations of three adipose tissue-derived substances: adiponectin, leptin, and interleukin-6 with incident CVD in a longitudinal population-based study, including extensive adjustments for traditional and metabolic risk factors closely associated with overweight and obesity. C-reactive protein (CRP) was used as a proxy for interleukin-6. Prospective population-based study of 6.502 participants, 51.9% women, aged 30–60 years, free of CVD at baseline, with a mean follow-up time of 11.4 years, equivalent to 74,123 person-years of follow-up. As outcome, we defined a composite outcome comprising of the first event of fatal and nonfatal coronary heart disease and fatal and nonfatal stroke. During the follow-up period, 453 composite CV outcomes occurred among participants with complete datasets. In models, including gender, age, smoking status, systolic blood pressure, treatment for hypertension, diabetes, body mass index (BMI), total cholesterol, high-density-lipoprotein cholesterol, homeostasis model assessment of insulin resistance, estimated glomerular filtration rate, adiponectin, leptin, and CRP, neither adiponectin (hazard ratio [HR] with 95% confidence interval [CI]: 0.97 [0.87–1.08] per SD increase, P = 0.60) nor leptin (0.97 [0.85–1.12] per SD increase, P = 0.70) predicted the composite outcome, whereas CRP was significantly associated with the composite outcome (1.19 [1.07–1.35] per SD increase, P = 0.002). Furthermore, in mediation analysis, adjusted for age and sex, CRP decreased the BMI-associated CV risk by 43% (95%CI 29–72). In this study, neither adiponectin nor leptin were independently associated with CVD, raising questions over their role in CVD. The finding that CRP was significantly associated with an increased risk of CVD and decreased the BMI-associated CVD risk substantially, could imply that interleukin-6-related pathways may play a role in mediating overweight- and obesity-related CVD.


  • Open Access

    Higher Serum Concentrations of N-Terminal Pro-B-Type Natriuretic Peptide Associate with Prevalent Hypertension whereas Lower Associate with Incident Hypertension

    by Ekim Seven, Lise L. N. Husemoen, Hans Ibsen, Nele Friedrich, Matthias Nauck, Kristian Wachtell, Allan Linneberg, Jørgen L. Jeppesen

    The role of the natriuretic peptides (NPs) in hypertension is complex. Thus, a higher blood NP concentration is a robust marker of pressure-induced cardiac damage in patients with hypertension, whereas genetically elevated NP concentrations are associated with a reduced risk of hypertension and overweight individuals presumably at high risk of hypertension have lower NP concentrations. To investigate the associations between serum N-terminal pro-B-type natriuretic peptide (NT-proBNP), used as a surrogate marker for active BNP, and prevalent as well as 5-year incident hypertension in a Danish general population sample. Cross-sectional and prospective population-based study. At baseline, among 5,307 participants (51.3% women, mean age 46.0±7.9 years) with a complete set of data, we recorded 1,979 cases with prevalent hypertension (PHT). Among 2,389 normotensive participants at baseline with a complete set of data, we recorded 324 cases with incident hypertension (IHT) on follow-up 5 years later. In models adjusted for age, sex, lifestyle, social, dietary, anthropometric, pulmonic, lipid, metabolic and renal risk factors, as well as heart rate and baseline blood pressure (only incident model), one standard deviation increase in baseline log-transformed NT-proBNP concentrations was on one side associated with a 21% higher risk of PHT (odds ratio [OR]: 1.21 [95% confidence interval (CI): 1.13-1.30], P), and on the other side with a 14% lower risk of IHT (OR: 0.86 [95%CI:0.76-0.98], P = 0.020). Higher serum concentrations of NT-proBNP associate with PHT whereas lower concentrations associate with IHT. This suggests that a lower amount of circulating BNP, resulting in diminished vasodilation and natriuresis, could be involved in the pathogenesis of hypertension in its early stages.


  • Five-year weight changes associate with blood pressure alterations independent of changes in serum insulin

    by Ekim Seven, Lise L.N. Husemoen, Kristian Wachtell, Hans Ibsen, Allan Linneberg, Jørgen L. Jeppesen

    Objective: In overweight-related hypertension, the effect of weight changes on blood pressure (BP) is believed to be mediated by insulin. To test this hypothesis, we studied 5-year changes in weight, BP, and insulin in a general population of Danish adults (n = 3443; mean age 45.7 ± 7.6 years). Methods: We assessed the glucose–insulin metabolism by a standard oral glucose tolerance test. We divided the antihypertensive and antidiabetic medication-free participants into three groups: weight loss (n = 515), weight stable (n = 1778), and weight gain (n = 1150). Results: Losing on average 6.5 kg body weight, the weight loss group experienced a 28.2% reduction [(95% confidence interval [CI] −31 to −25); P < 0.001] in fasting insulin and a 23.9% reduction [(95% CI −28 to −19); P < 0.001] in 2-h insulin. Gaining on average 6.4 kg, the weight gain group experienced a 12.5% increase [(95% CI 9 to 16); P < 0.001] in fasting insulin and 32.8% increase [(95% CI 28 to 38); P < 0.001] in 2-h insulin. Using linear regression adjusting for differences in sex, age, family history of hypertension, baseline BMI, SBP and DBP, lifestyle risk factors, and their 5-year changes, weight loss was associated with a decrease in SBP of −1.8 mmHg (95% CI −2.8 to −0.7), whereas weight gain with an increase in SBP of 1.9 mmHg (95% CI 1.2 to 2.6), both with P less than 0.001. Adding fasting insulin, 2-h insulin, Δfasting insulin, and Δ2-h insulin only marginally attenuated the association, and furthermore, none of the insulin variables was significantly associated with SBP or DBP (P ≥ 0.08). The results for changes in DBP were similar to SBP. Conclusion: Five-year weight changes associate with BP alterations independent of the insulin changes.


  • Overweight, adipocytokines and hypertension

    by Ekim Seven, Lise L.N. Husemoen, Kristian Wachtell, Hans Ibsen, Allan Linneberg, Jørgen L. Jeppesen

    The adipocytokines, leptin, adiponectin, and interleukin-6, which stimulate liver C-reactive protein (CRP) production, are regarded as potential candidate intermediates between adipose tissue and overweight-induced hypertension. We examined the associations between leptin, adiponectin, and CRP levels with both prevalent and 5-year incident hypertension (IHT) in a general population of Danish adults (n = 5868, 51.3% women, mean age 45.8 ± 7.9 years). We recorded 2195 prevalent and 379 incident cases of hypertension. In models including leptin, CRP, adiponectin, sex, age, lifestyle risk factors, lipids, insulin, hemoglobin A1c, and in the incident model also baseline heart rate and blood pressure, only leptin of the three candidate intermediates was significantly associated with both prevalent and IHT [odds ratio (OR) = 1.18, 95% confidence interval (CI) 1.06–1.32, P = 0.002, and OR = 1.24, 95% CI 1.01–1.54, P = 0.044] for one standard deviation increase in log-transformed leptin levels, respectively. Log-transformed CRP was associated with prevalent (OR = 1.16, 95% CI 1.07–1.26, P < 0.001) but not IHT (OR = 0.98, 95% CI 0.84–1.14, P = 0.76). Log-transformed adiponectin was neither associated with prevalent nor IHT (OR = 0.94, 95% CI 0.87–1.02, P = 0.11 and OR = 0.93, 95% CI 0.80–1.08, P = 0.33). Comparing the lowest with the highest quintile of sex-specific BMI levels, there was an almost two-fold increase in IHT (OR = 1.89, 95% CI 1.10–3.25, P = 0.023) in the fully adjusted model. The population attributable risk estimate of IHT owing to overweight was 31%. Leptin, but not adiponectin or CRP, may play a mediating role in overweight-induced hypertension. However, as BMI was a strong independent predictor of hypertension, other factors than leptin must be involved in the pathogenesis of overweight-related hypertension.